JOSE M VEGA
Medical Practice in Collegeville, PA

License number
Pennsylvania MD063377L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Collegeville, PA 19426

Professional information

Jose Vega Photo 1

Dihydroxy Open-Acid And Salts Of Hmg-Coa Reductase Inhibitors

US Patent:
6569461, May 27, 2003
Filed:
Apr 26, 2000
Appl. No.:
09/558800
Inventors:
Richard D. Tillyer - Cranford NJ
Paul J. Reider - Westfield NJ
Edward J. J. Grabowski - Westfield NJ
Feng Xu - Staten Island NY
Jose M. Vega - Trappe PA
Mandana Asgharnejad - Ambler PA
Assignee:
Merck Co., Inc. - Rahway NJ
International Classification:
A61K 900
US Classification:
424497, 424400, 424464, 424465, 424482, 424490
Abstract:
The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a compound selected from a dihydroxy open acid statin and a pharmaceutically acceptable salt or ester thereof in a delayed-release pharmaceutical dosage form to a patient in need of such treatment wherein substantial release of the compound from the dosage form is delayed until after passage of the dosage form through the stomach.


Jose Vega Photo 2

Dihydroxy Open-Acid Salt Of Simvastatin

US Patent:
2005011, Jun 2, 2005
Filed:
Nov 5, 2004
Appl. No.:
10/981866
Inventors:
Richard Tillyer - Cranford NJ, US
Paul Reider - Westfield NJ, US
Edward Grabowski - Westfield NJ, US
Feng Xu - Staten Island NY, US
Robert Wenslow - East Windsor NJ, US
Jose Vega - Trappe PA, US
Richard Varsolona - Scotch Plains NJ, US
International Classification:
A61K031/225, C07C069/66
US Classification:
514548000, 560180000
Abstract:
The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a crystalline hydrated form of the calcium salt of dihydroxy open acid simvastatin to a patient in need of such treatment. Methods for making the calcium salt of dihydroxy open acid simvastatin are also provided.


Jose Vega Photo 3

Dihydroxy Open-Acid And Salts Of Hmg-Co-A Reductase Inhibitors

US Patent:
2003021, Nov 13, 2003
Filed:
Apr 29, 2003
Appl. No.:
10/425154
Inventors:
Richard Tillyer - Cranford NJ, US
Paul Reider - Westfield NJ, US
Edward Grabowski - Westfield NJ, US
Feng Xu - Staten Island NY, US
Jose Vega - Trappe PA, US
Mandana Asgharnejad - Ambler PA, US
Assignee:
Merck & Co., Inc.
International Classification:
A61K031/225, A61K009/22, A61K009/16, A61K009/50
US Classification:
424/468000, 514/548000
Abstract:
The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a compound selected from a dihydroxy open acid statin and a pharmaceutically acceptable salt or ester thereof in a delayed-release pharmaceutical dosage form to a patient in need of such treatment wherein substantial release of the compound from the dosage form is delayed until after passage of the dosage form through the stomach.


Jose Vega Photo 4

Dihydroxy Open-Acid Salt Of Simvastatin

US Patent:
2003017, Sep 18, 2003
Filed:
Nov 13, 2002
Appl. No.:
10/293153
Inventors:
Richard Tillyer - Cranford NJ, US
Paul Reider - Westfield NJ, US
Edward Grabowski - Westfield NJ, US
Feng Xu - Staten Island NY, US
Robert Wenslow - East Windsor NJ, US
Jose Vega - Trappe PA, US
Richard Varsolona - Scotch Plains NJ, US
International Classification:
C07C069/34, A61K031/225
US Classification:
514/548000, 560/146000
Abstract:
The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a crystalline hydrated form of the calcium salt of dihydroxy open acid simvastatin to a patient in need of such treatment. Methods for making the calcium salt of dihydroxy open acid simvastatin are also provided.